ACBP Protein Drives Aging by Blocking Autophagy, Antibody Treatment Reverses Damage
Centenarians have 3x higher ACBP levels. Blocking this aging protein with antibodies prevents organ damage and cellular senescence.
Summary
Scientists discovered that acyl-CoA-binding protein (ACBP) accelerates aging by inhibiting autophagy, the body's cellular cleanup system. Centenarians showed 3x higher ACBP levels than younger adults, with levels spiking further during illness. In mice, blocking ACBP with antibodies prevented kidney damage, liver injury, and heart problems caused by chemotherapy drugs. The treatment also stopped cellular senescence—a key aging process—across multiple organs. This suggests ACBP could be a major driver of pathological aging that might be targetable with therapeutic interventions.
Detailed Summary
A groundbreaking study reveals that acyl-CoA-binding protein (ACBP) may be a key driver of pathological aging across multiple organ systems. This protein, which normally helps transport fats within cells, also acts as a hormone that inhibits autophagy—the body's critical cellular cleanup mechanism that removes damaged components and maintains cellular health.
Researchers analyzed blood samples from centenarians (average age 100) and found ACBP levels were three times higher than in healthy adults aged 30-48. Even more striking, hospitalized centenarians showed further elevated ACBP levels that correlated with kidney dysfunction and inflammatory markers associated with aging.
To test whether ACBP directly causes aging damage, scientists treated mice with antibodies that neutralize ACBP. This intervention prevented kidney injury from cisplatin chemotherapy, liver damage from high-fat diet plus toxins, and heart damage from doxorubicin. Crucially, the antibody treatment blocked cellular senescence—a hallmark of aging where cells stop dividing and secrete inflammatory factors.
Using advanced single-cell RNA sequencing, researchers found that ACBP neutralization restored normal gene expression patterns in heart cells, particularly genes involved in autophagy, fat metabolism, and mitochondrial function. This suggests ACBP disrupts multiple cellular maintenance pathways simultaneously.
The findings are significant because they identify a potentially druggable target for aging interventions. Unlike genetic approaches that require complex gene therapy, antibody treatments could theoretically be developed for human use. However, the research was conducted primarily in mice, and human trials would be needed to confirm safety and efficacy. The study also focused on pathological aging models rather than natural aging processes.
Key Findings
- Centenarians have 3x higher ACBP blood levels than younger adults
- ACBP antibody treatment prevents kidney, liver, and heart damage in mice
- Blocking ACBP stops cellular senescence across multiple organ systems
- ACBP neutralization restores autophagy and mitochondrial function genes
- Higher ACBP levels correlate with kidney dysfunction and inflammation
Methodology
Researchers measured ACBP in blood samples from centenarians and younger adults, then tested antibody neutralization in multiple mouse models of organ damage. Single-nucleus RNA sequencing analyzed gene expression changes in treated heart tissue.
Study Limitations
Studies were primarily conducted in mice using artificial aging models rather than natural aging. Human data was limited to observational blood measurements. Long-term safety of ACBP neutralization in humans remains unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.